Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: exploratory analysis of the proportional hazards assumption
Shugo Yajima, Soichiro Yoshida, Hitoshi Masuda, Yasuhisa Fujii · 2026
Read Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: exploratory analysis of the proportional hazards assumption by Shugo Yajima, Soichiro Yoshida, Hitoshi Masuda, Yasuhisa Fujii (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13263809.txt.
Description
Shugo Yajima and three co-authors reanalyzed a prostate cancer trial in a 2026 letter. The CAPItello-281 trial found that adding capivasertib to abiraterone slowed scan progression in men whose tumors lacked the PTEN gene. In the subgroup with total PTEN loss, the survival hazard ratio was 0.77, but the result was not statistically firm. Standard survival models assume the treatment effect stays proportional over time.
The survival curves hinted at late separation, which can break that assumption. The team rebuilt patient-level data from the published curves and ran formal checks. Two tests suggested the effect may grow with longer follow-up. They present the analysis as exploratory, urging care in how the trial result is read.
Catalog record
| CREATOR | Shugo Yajima, Soichiro Yoshida, Hitoshi Masuda, Yasuhisa Fujii |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 4 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |